North America Renal Denervation Devices Market - Growth, Trends, and Forecast (2022 - 2027)

Market Overview

North America Renal Denervation Devices Market is expected to register a CAGR of 3% during the forecast period. The major factors responsible for the growth of the renal denervation devices market include the rising prevalence of hypertension and the long-lasting effect of the procedure.

High blood pressure is called hypertension. The prevalence of hypertension has been observing a significant rise, over the past few years in North American Countries. Generally, blood pressure rises and falls throughout the day, but it can damage one’s heart and result in health problems if hypertension stays high for a long time.

According to the CDC (Centers for Disease Control and Prevention), about 75 million American adults (32%) have high blood pressure (hypertension), but only about half (54%) of them, with high blood pressure, have their condition under control. High blood pressure had been the primary contributing cause of death for more than 410,000 Americans, in 2014. CDC also stated that high blood pressure costs the country USD 48.6 billion, every year. The high prevalence is not just limited to the United State, owing to the fact that the Canada and Mexico also have a high rate of hypertension.

Thus, owing to all of the aforementioned factors, the market studied is expected to witness high growth, in the coming years.

Scope of the report

As per the scope of this report, renal denervation devices are one of several innovative device-based interventional therapies, which help to control blood pressure. It is safe, minimally invasive, and does not leave any implants behind. The market studied is segmented by technology and geography.

Report scope can be customized per your requirements. Click here.

Key Market Trends

The Ultrasound-based Segment is Expected to be the Fastest Growing Segment

· The ultrasound-based renal denervation devices are a minimally invasive procedure, using ultrasound to ablate nerves in the wall of the renal arteries, and it disrupts the transmission of nerve impulses to and from the kidney and lowers blood pressure. Additionally, according to the first randomized trial to compare the techniques (RADIOSOUND-HTN trial), the ultrasound-based renal denervation (RDN) approach has led to greater reductions in blood pressure than radiofrequency ablation in patients, with resistant hypertension. The rising prevalence of hypertension is expected to boost the overall growth of the market studied.

· COVID-19 has negatively impacted the number of procedures and the production of the devices in North America. Due to the fear of transmission of the virus, many hospitals have canceled the procedures and the manufacturing and supply chain was disturbed due to the lockdown worldwide. Additionally, many trials and product approvals have been pending for the year, which is impacting market growth.

To understand key trends, Download Sample Report